Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 3/20 | 0.54 |
| ▸ | CMA1 | P23946 | 2/20 | 0.53 |
| ▸ | AHR | P35869 | 2/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | HBB | P68871 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 3/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.36 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19238957 | 0.81 | ALDH1A1 (0.41) | CMA1AHRMETAP1KMT2AMEN1 | |
| SCHEMBL19238960 | 0.80 | AHR (0.53) | TDP2CMA1AHRMETAP1PGR | |
| SCHEMBL20889841 | 0.78 | PARP1 (0.40) | TDP2CMA1AHRMAPTPARP1 | |
| SCHEMBL20883888 | 0.78 | HPGD (0.49) | TDP2KMT2AMEN1MAPTALOX15 | |
| SCHEMBL24620670 | 0.78 | ALDH1A1 (0.37) | TDP2CMA1AHRMAPTHSD17B10 | |
| SCHEMBL19206207 | 0.76 | TDP2 (0.50) | TDP2CMA1AHRBRD4METAP1 | |
| SCHEMBL1951226 | 0.76 | TDP2 (0.60) | TDP2PGRKMT2AMEN1MAPT | |
| SCHEMBL1953250 | 0.75 | HTR2A (0.48) | TDP2AHRBRD4 | |
| SCHEMBL8370875 | 0.75 | TDP2 (0.47) | TDP2CMA1AHRBRD4METAP1 | |
| Methylamine SCHEMBL27858404 | 0.72 | AHR (0.89) | TDP2CMA1AHRBRD4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125280-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | CYTOKINETICS, INCORPORATED | 2023-04-27 | — | — | US | disclosed |
| US-20230125280-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | CYTOKINETICS, INCORPORATED | 2023-04-27 | — | — | US | disclosed |
| US-20230125280-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | CYTOKINETICS, INCORPORATED | 2023-04-27 | — | — | US | disclosed |
| US-11479561-B2 | Tetrahydroisoquinoline derivatives | CYTOKINETICS, INCORPORATED (US) | 2022-10-25 | — | — | US | disclosed |
| US-11479561-B2 | Tetrahydroisoquinoline derivatives | CYTOKINETICS, INCORPORATED (US) | 2022-10-25 | — | — | US | disclosed |
| EP-4032877-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | Cytokinetics, Incorporated (US) | 2022-07-27 | — | — | EP | disclosed |
| EP-3413892-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES | CYTOKINETICS INC (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3413892-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES | CYTOKINETICS INC (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-113666938-A | Tetrahydroisoquinoline derivatives | 细胞动力学股份有限公司 | 2021-11-19 | — | — | CN | disclosed |
| CN-109069498-B | Tetrahydroisoquinoline derivatives | 细胞动力学股份有限公司 | 2021-08-17 | — | — | CN | disclosed |
| WO-2017139526-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | ASTELLAS PHARMA INC. (US) | 2017-08-17 | — | — | WO | disclosed |
| US-7713994-B2 | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo,1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihyro-3 (2H)-isoquinolones and methods of use thereof | WYETH LLC (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713994-B2 | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo,1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihyro-3 (2H)-isoquinolones and methods of use thereof | WYETH LLC (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713994-B2 | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo,1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihyro-3 (2H)-isoquinolones and methods of use thereof | WYETH LLC (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1963273-A2 | SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20080085890-A1 | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof | WYETH (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080085890-A1 | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof | WYETH (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080085890-A1 | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof | WYETH (US) | 2008-04-10 | — | — | US | disclosed |
| WO-2007075783-A2 | SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITOR | WYETH (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075783-A2 | SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITOR | WYETH (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125280-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | TNNC1, TNNI3, TNNT2 | TDP2 176/4885CMA1 2020/4885AHR 3711/4885 |
| US-20080085890-A1 | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof | SULT1E1, RECQL, HAX1 | TDP2 511/4885CMA1 3659/4885AHR 1357/4885 |
| US-11479561-B2 | Tetrahydroisoquinoline derivatives | TNNC1, TNNI3, TNNT2 | TDP2 176/4885CMA1 2020/4885AHR 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.